

CytRx Corp (CYTR) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/C49085EBA50EN.html
Date:	May 30, 2018
Pages:	47
Price:	US\$ 125.00
ID:	C49085EBA50EN

CytRx Corp (CYTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

CytRx Corp (CytRx) is a clinical state is a biopharmaceutical company focusing on the research and development of novel treatments for cancer. The company's oncology based product comprises of its lead drug product candidate, aldoxorubicin (formerly INNO-206). Aldoxorubicin is a pro-drug of the commonly prescribed chemotherapeutic doxorubicin, designed to reduce adverse events by controlling release and preferentially targeting the tumor. Its other new albumin-binding drug conjugates are under pre-clinical development. The company conducts discovery and translational research at its discovery laboratory located in Freiburg, Germany. It has a strategic alliance with KTB Tumorforschungs GmbH. CytRx is headquartered in Los Angeles, California, the US.

CytRx Corp Key Recent Developments

May 03,2018: CytRx Names Eric L. Curtis as Its President and Chief Operating Officer

Apr 18,2018: CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting

Apr 09,2018: CytRx to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR Drug Candidates at the AACR 2018 Conference

Mar 19,2018: CytRx Announces 2017 Financial Results

Mar 15,2018: CytRx Selects Four New LADR Ultra High Potency Drug Candidates for Advancement Toward Clinical Trials

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

CytRx Corp - Key Facts
CytRx Corp - Key Employees
CytRx Corp - Key Employee Biographies
CytRx Corp - Major Products and Services
CytRx Corp - History
CytRx Corp - Company Statement
CytRx Corp - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
CytRx Corp - Business Description
CytRx Corp - SWOT Analysis
SWOT Analysis - Overview
CytRx Corp - Strengths
CytRx Corp - Weaknesses
CytRx Corp - Opportunities
CytRx Corp - Threats
CytRx Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
CytRx Corp, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

May 03, 2018: CytRx Names Eric L. Curtis as Its President and Chief Operating Officer
Apr 18, 2018: CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting
Apr 09, 2018: CytRx to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR Drug Candidates at the AACR 2018 Conference
Mar 15, 2018: CytRx Selects Four New LADR Ultra High Potency Drug Candidates for Advancement Toward Clinical Trials
Mar 01, 2018: CytRx Announces Key Addition to Corporate Development Team
Dec 06, 2017: CytRx Announces Filing of Key Provisional Patent Applications for Ultra-High Potency LADR Drug Candidates
Nov 13, 2017: CytRx Provides Business Update and Announces New Shareholder Initiatives
Nov 08, 2017: CytRx Reports Third Quarter 2017 Financial Results
Nov 06, 2017: CytRx Announces Strategic Realignment of Clinical Development Team
Nov 02, 2017: CytRx Highlights Recent Progress at Freiburg, Germany, Laboratory and Provides Update for Oncology Pipeline

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

CytRx Corp, Key Facts
CytRx Corp, Key Employees
CytRx Corp, Key Employee Biographies
CytRx Corp, Major Products and Services
CytRx Corp, History
CytRx Corp, Key Competitors
CytRx Corp, Ratios based on current share price
CytRx Corp, Annual Ratios
CytRx Corp, Annual Ratios (Cont.1)
CytRx Corp, Interim Ratios
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
CytRx Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

CytRx Corp, Performance Chart (2013 - 2017)
CytRx Corp, Ratio Charts
CytRx Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
CytRx Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

AstraZeneca Plc
CTI BioPharma Corp
FirstString Research Inc
GlaxoSmithKline LLC
Johnson & Johnson
Pharmacyclics Inc
Sanofi
ZIOPHARM Oncology Inc

I would like to order:

Product name: CytRx Corp (CYTR) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/C49085EBA50EN.html>
Product ID: C49085EBA50EN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/C49085EBA50EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**